SCHEMBL16615838

SCHEMBL16615838

Cc1ncc(CNC(=O)c2ccc(CNS(=O)(=O)c3csc4ccccc34)cn2)s1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRIN2A Q12879 4/20 0.47
GRIN1 Q05586 2/20 0.47
GRIN2B Q13224 1/20 0.44
SCD O00767 2/20 0.39
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 1/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HTR2C P28335 1/20 0.36
PIK3CA P42336 1/20 0.36
NFATC1 O95644 1/20 0.36
SLC8A1 P32418 1/20 0.35
PDPK1 O15530 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16598218 0.84 GRIN2A (0.55) GRIN2AGRIN1GRIN2BSCDHTT
SCHEMBL16615836 0.81 GRIN2A (0.49) GRIN2AGRIN1GRIN2BALDH1A1KMT2A
SCHEMBL16615839 0.81 GRIN2A (0.49) GRIN2AGRIN1GRIN2BSCDHTT
SCHEMBL16615803 0.81 GRIN2A (0.52) GRIN2AGRIN1GRIN2BPOLBHPGD
SCHEMBL16615951 0.81 GRIN2A (0.54) GRIN2AGRIN1GRIN2BSCDPOLB
SCHEMBL16615799 0.80 GRIN2A (0.50) GRIN2AGRIN1GRIN2BSCDHTT
SCHEMBL16615831 0.80 GRIN2A (0.54) GRIN2AGRIN1GRIN2BSCDPOLB
SCHEMBL16615835 0.80 KMT2A (0.53) GRIN2AGRIN1GRIN2BPOLBHPGD
SCHEMBL16598124 0.79 GRIN2A (0.60) GRIN2AGRIN1GRIN2BSCDHTT
SCHEMBL16615841 0.79 SMN1; SMN2 (0.56) GRIN2AGRIN1ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963434-B2 N-arylmethyl sulfonamide negative modulators of NR2A LUC THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A NOVARTIS AG (CH) 2016-10-27 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. 2015-05-21 US disclosed
WO-2015048503-A2 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A MNEMOSYNE PHARMACEUTICALS, INC. (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311782-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885
US-20150141433-A1 N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A GRIN2A, GRIN2B, NR2C2 GRIN2A 1/4885GRIN1 5/4885GRIN2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.